Each heavy chain is attached to a light ... and miniaturized antibody therapeutic molecules is the least mature. Only five third-generation molecules have entered clinical development under ...

Harbour BioMed reported total revenue of US$38.1 million for the year ended December 31, 2024, with an overall profit of approximately US$2.7 million. The company has been profitable for two ...

fully human heavy chain-only antibodies that are approximately half the size of conventional IgGs, offering significant ...

Harbour BioMed inks collaboration with AstraZeneca to discover and develop next-generation therapeutic antibodies: Shanghai & Rotterdam, The Netherlands Tuesday, March 25, 2025, 1 ...